MedTrace Logo

Neoadjuvant Chemotherapy Docetaxel With or Without SELUMETINIB in Patients With Triple Negative Breast Cancer

NCT02685657 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 164

Last updated 2016-02-22

No results posted yet for this study

Summary

The purpose of this study is to increase survival of patients with early and locally advanced triple-negative breast cancer adding selumatinib to standard preoperative chemotherapy regimen.

Conditions

Interventions

DRUG

Drug: Selumetinib

DRUG

Doxorubicin

DRUG

Cyclophosphamide

DRUG

Docetaxel

Sponsors & Collaborators

  • Russian Society of Clinical Oncology

    collaborator UNKNOWN

  • Russian Academy of Medical Sciences

    lead OTHER

Principal Investigators

  • Mona Frolova · Russian Cancer Research Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-09-30
Primary Completion
2018-01-31

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02685657 on ClinicalTrials.gov